RUNX1 and acute myeloid leukemia: Experimental studies suggest that LSD1 targeting is a possible therapeutic strategy in AML, leading to impaired self-renewal and proliferation as well as increased differentiation and apoptosis of primary AML stem cells, especially AMLs with KTM2A and RUNX1 rearrangements or erythroid/megakaryoblastic differentiation block [88].